{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-010633","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2026-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.977027+00:00","generated_at":"2026-05-16T04:22:56.612353+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ocular Therapeutix Q4 net loss $0.29/shr; SOL-1 data readout at Macula Society Feb 25-28","bullets":["Q4 2025 net revenue $13.3M, down 22.4% YoY; full year $52.0M, down 18.5%.","Net loss Q4 $64.7M ($0.29/shr), full year $265.9M ($1.42/shr); R&D spend rose to $50.8M.","SOL-1 Phase 3 wet AMD superiority data to be presented at Macula Society meeting Feb 25-28, 2026.","Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1, pending positive results and FDA interactions.","Cash $737.1M as of Dec 31, 2025; raised $475M in Sep 2025 equity offering; runway into 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-010633","json":"https://secwatch.observer/filing/0001104659-26-010633.json","markdown":"https://secwatch.observer/filing/0001104659-26-010633.md","text":"https://secwatch.observer/filing/0001104659-26-010633.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465926010633/0001104659-26-010633-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465926010633/tm265061d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:22:56.612353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}